Study: NCT06352632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-dose intravenous tenecteplase
Description: Standard-dose intravenous tenecteplase (0.25 mg/kg body weight); one-time IV bolus injection soon after randomisation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous tenecteplase
Description: Low-dose intravenous tenecteplase (0.18 mg/kg body weight); one-time IV bolus injection soon after randomisation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intravenous tenecteplase
Description: No intravenous tenecteplase only in subjects on direct oral anticoagulant (DOACs) or those planned for emergency endovascular thrombectomy (EVT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative Blood Pressure Control
Description: No or minimal Systolic Blood Pressure (SBP) control; SBP reduction by 5-10mmHg or a target of 175-180mmHg if very-high baseline SBP (≥180mmHg); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Blood Pressure Control
Description: SBP reduction by 10-20mmHg or a target of 160 ± 5, whichever is higher; no control if low-high baseline SBP (150-160mmHg); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Blood Pressure Control
Description: SBP reduction by 30-50mmHg or a target of 140±5 mmHg, whichever is higher after endovascular thrombectomy (EVT); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 100 mL of 0.9% normal saline, administered as a single IV infusion with a 20-minute dosing duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NoNO-42
Description: NoNO-42 at weight-based dosing - 2.6 mg/Kg, administered as a single IV infusion with a 20-minute dosing duration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No deferoxamine mesylate and no colchicine
Description: No deferoxamine mesylate and no colchicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine mesylate only
Description: Deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine only
Description: 0.5mg of oral colchicine daily for 30 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Both deferoxamine mesylate and colchicine
Description: Deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days; plus 0.5mg of oral colchicine daily for 30 consecutive days